Immusoft Lands $15M CIRM Grant to Advance Engineered B Cell Therapy for MPS I
Immusoft just scored its second CIRM grant — and its engineered B cells are doing something no other cell therapy has done: safe re-dosing.
Category Voyager Articles
Centivax Raises $37M to Chase Universal Flu Vaccine Into Phase 2
Merck paid $9.2 billion for Cidara's universal flu program. Now Centivax raises $37M — with the Stripe founders backing them — to push its own into Phase 2.
Aurinia Acquires Kezar Life Sciences in Kevin Tang’s Biotech Comeback Play
Kevin Tang tried to buy Kezar once and got rejected. Now he's back — as Aurinia's CEO — and this time he got the deal done.
Ollin Biosciences’ OLN324 Beats Roche’s Vabysmo in Head-to-Head Retinal Trial
A Phase 1b head-to-head study shows OLN324 outperforming Vabysmo in wet AMD and DME — and the CEO helped build the drug it just beat.
Stop Inhibiting. Start Destroying.
TRIANA Biomedicines doses the first patient with TRI-611, a brain-penetrant molecular glue degrader that eliminates ALK fusion proteins — not just blocks them.
$787 Million Says AI Can Design Better Biologics Than You
An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.
Teaching a Gene Editor to Optimize Itself
Specific Biologics just got government funding to build a machine learning layer on top of its Dualase gene editing platform — targeting repeat expansion diseases like ALS.
Molecular Glues Were Discovered by Accident. Not Anymore.
Molecular glues are biotech's hottest modality and its hardest to design rationally. Ternary thinks AI can change that.
What If B-Cell Depletion Didn’t Need T Cells at All?
Commit Biologics raises €21.5M to weaponize the complement system against B cells — no cytokine storm required.
The Splice Between Gene Editing and Gene Therapy
Tacit Therapeutics launches with $19M to build RNA splicing therapies that fix mutations without touching DNA.